257 related articles for article (PubMed ID: 29699840)
1. Iron toxicity - Its effect on the bone marrow.
Isidori A; Borin L; Elli E; Latagliata R; Martino B; Palumbo G; Pilo F; Loscocco F; Visani G; Cianciulli P
Blood Rev; 2018 Nov; 32(6):473-479. PubMed ID: 29699840
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
[TBL] [Abstract][Full Text] [Related]
3. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy for a case of transfusion-independent MDS-RARS with significant iron overload.
Ohashi H; Arita K; Suzuki Y; Tomita A; Naoe T; Hattori A; Tatsumi Y; Kato K; Nagai H
Int J Hematol; 2013 Jan; 97(1):151-3. PubMed ID: 23208667
[No Abstract] [Full Text] [Related]
5. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
6. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
Koh KN; Park M; Kim BE; Im HJ; Seo JJ
J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.
Lee JW
Int J Hematol; 2008 Jul; 88(1):16-23. PubMed ID: 18604581
[TBL] [Abstract][Full Text] [Related]
8. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
[TBL] [Abstract][Full Text] [Related]
9. The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice.
Okabe H; Suzuki T; Uehara E; Ueda M; Nagai T; Ozawa K
Eur J Haematol; 2014 Aug; 93(2):118-28. PubMed ID: 24628561
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
Cazzola M; Della Porta MG; Malcovati L
Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
[TBL] [Abstract][Full Text] [Related]
11. Free iron catalyzes oxidative damage to hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload patients.
Lu W; Zhao M; Rajbhandary S; Xie F; Chai X; Mu J; Meng J; Liu Y; Jiang Y; Xu X; Meng A
Eur J Haematol; 2013 Sep; 91(3):249-261. PubMed ID: 23772810
[TBL] [Abstract][Full Text] [Related]
12. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
14. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
15. [Bone marrow failure syndrome (idiopathic hematopoietic disorders): progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 8. Iron overload by blood transfusion].
Suzuki T; Ozawa K
Nihon Naika Gakkai Zasshi; 2012 Jul; 101(7):1986-93. PubMed ID: 22897003
[No Abstract] [Full Text] [Related]
16. Iron overload in patients with myelodysplastic syndromes.
Jensen PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
[TBL] [Abstract][Full Text] [Related]
17. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
19. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in myelodysplastic syndromes.
Mahesh S; Ginzburg Y; Verma A
Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
